Anonymous
Guest
Anonymous
Guest
It is my understanding that most every other pharmaceutical and biotech company have begun utilizing contract sales forces to save money by replacing expensive tenured sales representatives with motivated younger salespeople at significant savings for both the short-term and long-term. By doing so, the cost savings are enormous. They will no longer need to offer company pensions, expensive company fleet cars with all the expenses that go with them, and more importantly the salaries for the contract sales representatives will be 1/4 of what they're paying their less motivated tenured sales representatives. In this day and age of corporate outsourcing it is a no-brainer that all companies do whatever it takes to maintain an attractive corporate portfolio.
As a stockholder in jnj I am deeply concerned that jnj is not maximizing all their savings potential, particularly when there are issues with key products such as tylenol and many of their products going off patent in the next few years.
I believe jnj is falling short of the other pharmaceutical and biotech companies by not uilizing the proper measures to maximize the corporate bottom line.
As a stockholder in jnj I am deeply concerned that jnj is not maximizing all their savings potential, particularly when there are issues with key products such as tylenol and many of their products going off patent in the next few years.
I believe jnj is falling short of the other pharmaceutical and biotech companies by not uilizing the proper measures to maximize the corporate bottom line.